| Outcome |
# patients(# trials) |
Control baseline m |
Wt absolute change |
Relative % change |
NNT (B) or NNT (H) |
Statistical Sig |
Quality of Evidence |
| SLEDAI (mild/moderate) (0‐105) |
148(2) |
6.55* |
0.6% reduction (0.6 points less on a scale of 0‐105) |
9.3% improvement |
NA |
not statistically significant |
Gold |
| 95% confidence interval |
|
|
‐2.12 to 0.89 |
|
|
|
|
| SLEDAI (severe) (0‐105) |
19(1) |
9.4 |
6% reduction (6.4 points less on a scale of 0‐105) |
68% improvement |
3 |
borderline statistically significant |
Silver |
| 95% confidence interval |
|
|
‐13.12 to 0.32 |
|
|
|
|
| HRQoL (mild/moderate) Patient Global (0‐100) |
148 (2) |
28.5 |
11.5% reduction (11.5 point reduction on a scale of 0‐100) |
40.4% improvement |
5 |
statistically significant |
Gold |
| 95% confidence interval |
|
|
‐19.1 to ‐3.8 |
|
|
|
|
| HRQoL (severe) (0‐100) |
19 (1) |
52.6 |
0.2% reduction (0.2 point reduction on a scale of 0‐100) |
0.4% improvement |
NA |
not statistically significant |
Silver |
| 95% confidence interval |
|
|
‐3.7 to 3.3 |
|
|
|
|
| Legend: |
SLEDAI ‐ SLE disease activity index
HRQOL ‐ Health Related Quality of Life |
|
|
|
NA=not applicable |
|
|
